Epilepsy Research

ObjectiveSeizure dogs are service animals trained to respond supportively to seizures in people with epilepsy; some are also trained to detect seizure-specific scents, particularly ictal volatile organic compounds (VOCs). This survey study examines feasibility and safety of incorporating a seizure service dog (SSD) into an inpatient setting, as well as patient perceptions of having an SSD in the Epilepsy Monitoring Unit (EMU). MethodsOur SSD underwent specialized training for seizure response and seizure recognition based on seizure-specific VOCs, and accompanied his epileptologist owner in the EMU on rounds for over four years prior to the study. We administered surveys to patients hospitalized in the EMU before and after interactions with a trained seizure dog. The surveys assessed the patients comfort with the dog, perceived usefulness of service dogs, safety, and tolerability. Select case examples are also presented in which seizure dog spontaneously alerted prior to epileptic seizures; seizures later confirmed by independent EEG review. ResultsPatient responses underscored overall high enthusiasm for seizure dog therapy, with 93% of participants reporting feeling "very comfortable" or "extremely comfortable" with a seizure dog present. No adverse concerns or negative experiences were reported by participants. 91% reported personally experiencing benefits of working with the seizure dog, citing emotional and comfort benefits during their hospitalization. 94% of participants were comfortable with physical contact with the dog or had no proximity preference. ConclusionThese findings suggest that seizure service dogs can be safely integrated into the inpatient EMU setting and have potential to enhance patient care and emotional well-being during EMU monitoring. Summary PointsO_LITotal of 98 patients admitted to EMU were surveyed about opinions regarding seizure dogs and comfort with integration of seizure dog in EMU setting, with 35 patients completing post-test surveys after interacting with the seizure dog. C_LIO_LI93% of surveyed EMU patients completing post-test surveys felt very or extremely comfortable with the seizure dog; no negative experiences or safety concerns were reported. C_LIO_LI91% reported personally experiencing emotional benefits of working with the seizure dog. C_LIO_LISelect case examples demonstrate that the trained seizure dog in our study may be able to spontaneously identify epileptic seizures. C_LI

ImportanceEpilepsy is one of the most common neurological disorders globally. A significant proportion of patients fail to achieve effective seizure control with medication and ultimately develop drug-resistant epilepsy, particularly mesial temporal lobe epilepsy (MTLE). While surgical resection and laser interstitial thermal therapy (LITT) are effective treatments for drug-resistant MTLE, these procedures may be associated with severe adverse events. In contrast, allogeneic induced pluripotent stem cell (iPSC)-based therapy is expected to offer a novel, potentially safer therapeutic approach with fewer side effects for patients with drug-resistant MTLE. ObjectiveTo evaluate the safety and preliminary efficacy of a single intracranial injection of ALC05 (iPSC-derived GABAergic interneurons) in patients with unilateral MTLE, and to assess the therapeutic effects of different dosage levels. Design, Setting, and ParticipantsThis single-center, randomized, double-blind, Phase 1 clinical trial will enroll 12 subjects with unilateral MTLE. All subjects will be randomly assigned to either the low-dose or high-dose group in a 1:1 ratio. To minimize risks at each dose level, the first subject in each dose group will be monitored for safety for at least 3 months following ALC05 injection and must demonstrate acceptable safety and tolerability before the remaining subjects are enrolled. The primary outcome will be the incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Secondary outcomes include cell engraftment and survival, responder rate, and seizure frequency. The follow-up period for this study is 1 year. After completing the follow-up period within this study, subjects will enter a 15-year long-term safety follow-up. DiscussionMTLE remains a significant challenge in neurology. The results of this study will provide critical data regarding the feasibility and preliminary efficacy of ALC05 in treating MTLE and may offer a transformative therapeutic option for this condition.

Genetic deletion or pharmacological blockade of P2X7 receptors (Rs) counteract status epilepticus (SE) in animal models of epilepsy. It is, however, unclear whether P2X7Rs are localized at astrocytes or neurons, and the reason for astrocytic atrophy arising in consequence of SE is also ambiguous. We conducted a combined morphological/electrophysiological study in order to investigate these issues. It has been shown that kainic acid (KA)-induced SE in mice led to the atrophy of hippocampal astrocytes and at the same time to the decrease of ezrin immunoreactivity and its co-expression with mCherry, whose synthesis has been initiated by the injection of a virus complex. mCherry expression in astrocytes enabled us to study changes in cell somata and processes brought about by KA-injection. Ezrin is a plasmalemmal-cytoskeleton linker; its grade of expression indicates changes in the existence/function of small peripheral astrocytic processes. Pretreatment of mice with the blood-brain barrier-permeable P2X7R antagonist JNJ-47965567 prevented the SE-induced damage of astrocytes. KA caused a potentiation of dibenzoyl-ATP (Bz-ATP) currents in astrocytes but not neurons of the hippocampus. This effect was also abolished by pre-treatment of mice with JNJ-47965567 before applying KA, although no similar changes occurred in hippocampal CA1 neurons. The measurement of spontaneous postsynaptic currents (sPSCs) and spontaneous excitatory postsynaptic currents (sEPSCs) indicated a presynaptic facilitation of neurotransmitter release by Bz-ATP. In conclusion, we suggest that astrocytic P2X7Rs are the primary target of ATP release from damaged CNS cells in the hippocampus which simultaneously causes damage to astrocytic somata and processes.

AbstractO_ST_ABSBackgroundC_ST_ABSInvasive neuromodulation may be used in patients if seizure medications fail and surgery is not an option. However, moderate success is achieved and improved paradigms are required. The medial septum has been considered a suitable target for the treatment of temporal lobe epilepsy due to its location and connectivity. ObjectiveTo assess the effect of medial septum low-frequency deep brain stimulation to inhibit pentylenetetrazole (PTZ)-induced seizures. MethodsMale Sprague-Dawley rats were stereotaxically implanted in the medial septum and left dorsal hippocampus one week prior to the experimental protocols. Then, the animals were assigned to three experimental groups: 1) 10 Hz + PTZ (n=3); 2) 5 Hz + PTZ (n=7); and 3) 5 Hz (n=7). The stimulation consisted of a 30 min train of biphasic square-wave pulses at a current of 150 {micro}A and a pulse duration of 1 ms. Rats were subjected to the experimental protocol every 24 h for seven consecutive days. ResultsSubjects exposed to the 10 Hz died after the first PTZ injection. The 5 Hz stimulation not only prevented the animals death, but also induced a protective effect against generalization. Surprisingly, in both 5 Hz groups, septal and hippocampal spike-wave-like discharges were detected (mainly integrated by theta oscillations). This phenomenon was correlated with the generalization avoidance. ConclusionsWhile this study is preclinical in nature, our findings underscore the potential of using low-frequency medial septum stimulation for future clinical applications. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/720729v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@53482org.highwire.dtl.DTLVardef@1ba5d7corg.highwire.dtl.DTLVardef@4f999aorg.highwire.dtl.DTLVardef@1ed6744_HPS_FORMAT_FIGEXP M_FIG C_FIG

ImportanceImplantable sub-scalp EEG systems with a small number of channels have emerged as promising solutions for long-term seizure monitoring in patients with epilepsy. How seizure detection performance varies by montage configuration is unknown. ObjectiveTo quantify how automated seizure detection performance differs between full and reduced montages, and how these differences vary by epilepsy characteristics. DesignRetrospective cross-sectional study. SettingSingle-center at the Hospital of the University of Pennsylvania Epilepsy Monitoring Unit (EMU). ParticipantsEEG data from 2281 consecutive EMU admissions between January 2017 and December 2024 were screened. Admissions with at least one annotated seizure and one interictal clip [≥]20 minutes from any seizure were included. ExposureComputational simulation of published sub-scalp device montages using standard 10-20 EEG channels. Main Outcomes and MeasuresThe primary outcome was event-based F1 scores evaluated for three published seizure detectors--a one-class support vector machine (SVM), a convolutional neural network (SPaRCNet), and a long short-term memory autoregressive model (NDD)--across montages. ResultsA total of 466 admissions from 436 patients (mean [SD] age, 39.0 [14.4] years; 54.4% female) met inclusion criteria, comprising 1683 seizures and 1527 interictal clips. SPaRCNet achieved the highest performance (mean [SD] F1, 0.61 [0.30]), followed by NDD (0.56 [0.28]) and SVM (0.39 [0.25]). Performance decreased by at most 0.09 with reduced montages, depending on detectors. Patient factors accounted for the largest proportion of performance variance (29.2%), followed by detector choice (10.3%). Montage effects were minimal (0.4%), despite variation in optimal montage across detectors. Reduced-montage performance correlated moderately to highly with full-montage performance ({rho}=0.29-0.73), suggesting full-montage performance could help identify patients suitable for sub-scalp devices. Missed seizures were associated with lower amplitude and bandpowers than detected seizures, though they remained distinguishable from interictal data. Conclusions and RelevanceAutomated seizure detection achieved comparable accuracy, with only modest reductions, under simulated reduced montages. Performance differences were driven primarily by detector- and patient-level factors rather than montage. These findings support the feasibility of accurately detecting seizures with published sub-scalp devices and highlight the need for improved algorithms to optimize performance. Key FindingsO_ST_ABSQuestionC_ST_ABSHow do automated seizure detection algorithms perform with reduced-channel montages simulating published sub-scalp devices? FindingsIn this retrospective cross-sectional study, seizure detection performance decreased only modestly on reduced montages relative to the full montage (absolute F1 change -0.09 to 0.014), whereas patient- and algorithm-level factors accounted for most of performance variance (29.2% and 10.3%, respectively). Algorithm performance on full montage recordings was moderately correlated with performance on reduced channel montages ({rho}=0.29-0.73). MeaningReduced-montage sub-scalp devices are promising for ultra-long-term monitoring, but best performance requires selecting the right patients. Patient-specific seizure detectors will likely be required to optimize long-term performance.

ObjectiveVagus nerve stimulation (VNS) is an established neuromodulation therapy used in the management of drug-resistant epilepsy (DRE), or when other intracranial surgical modalities have not reduced seizure burden. We evaluated whether prior intracranial surgery for epilepsy influences safety and effectiveness outcomes with adjunctive VNS, using real-world data from the CORE-VNS study. MethodsCORE-VNS (NCT03529045), a prospective, multicenter, international observational study, was designed to collect data on seizure and non-seizure outcomes in patients with DRE treated with VNS. Participants were identified as having or not having undergone prior intracranial brain surgery for epilepsy (ICSE) and received an initial VNS implant. Baseline seizure frequency data and patient-reported outcome measures were collected at 3, 6, 12, 24, and 36 months. This analysis compared the baseline data for VNS therapy and safety outcomes at 36 months. ResultsAmong 531 participants implanted with VNS, prior ICSE was performed in 84. Median percentage seizure reductions at 36 months for all seizures (76.6% and 76.3%), all focal seizures (83.3% and 71.8%), and all generalized seizures (77.8% and 76.2%) were found to be similar between those without and with a history of ICSE, respectively. The 50% responder rate for all seizures reported at baseline was similar, 64.8% and 61.8%, in both groups and complete seizure freedom was reported by 17.9% and 8.8%, respectively. Implant-related adverse events (AE) and serious AE rates were similar between groups. ConclusionVNS was associated with clinically meaningful seizure reductions and showed a consistent safety profile irrespective of the history of ICSE. Prior ICSE should not be a contraindication to the consideration of VNS.

Temporal lobe epilepsy (TLE) is a heterogeneous disorder with most clinical presentations involving unilateral or bilateral hippocampal seizure onsets. Antiseizure medications are often ineffective for TLE, and epilepsy surgery can have variable outcomes. Risk factors for TLE are readily identifiable and typically precede chronic epilepsy, providing a window of opportunity for preventative treatments. However, there are currently no clinically approved anti-epileptogenic therapies. In this study, we investigate the role of Wnt signaling in epileptogenesis using two mouse TLE models, the intrahippocampal kainate model of unilateral TLE (IHK), and the intraperitoneal kainate model of bilateral TLE (IPK). We specifically examined adult-born immature dentate granule cells as these cells have been heavily implicated in the pathogenesis of TLE and clinical TLE is typically initiated in adulthood. We observed that adult-born immature dentate granule cells undergo pathological morphological changes during epileptogenesis in both the IHK and IPK models of TLE. When compared across epileptogenic zones, however, these changes differed between the two models. Wnt signaling also decreased in these cells in epileptic mice during the epileptogenic period. When mice were treated with SB415286, a highly selective Wnt activator, Wnt signaling in immature dentate granule cells was restored to baseline levels and pathological remodeling changes were reduced in both models. These data therefore suggest that a reduction in Wnt signaling in immature dentate granule cells plays an etiological role in epileptogenesis, and that restoring Wnt signaling using Wnt activating drugs or alternative agents may have therapeutic potential as an anti-epileptogenic strategy in TLE.

Mutations in DOCK7 have been identified in individuals with epileptic encephalopathies. Given that epileptic encephalopathies are a set of disorders that result in seizure activity and associated cognitive and behavioral impairments, we investigated the role of Dock7 in seizure susceptibility and flurothyl kindling using the repeated flurothyl seizure model in mice. Male and female Dock7+/+ and Dock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 mice were subjected to 8 daily flurothyl exposures (kindling, induction phase) followed by a 28-day incubation period and a subsequent flurothyl rechallenge (retest). No significant differences were observed in baseline myoclonic jerk or generalized seizure thresholds between genotypes or sexes. However, over the kindling period, male Dock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 mice exhibited slightly higher myoclonic jerk and generalized seizure thresholds compared to Dock7+/+ males across trials. Female mice showed similar trends, but the differences were only significant for generalized seizure thresholds. Following the 28-day incubation period and flurothyl retest, male mice of both genotypes maintained their seizure thresholds upon retest. Dock7+/+ female mice showed increased myoclonic jerk and generalized seizure thresholds during retest, while Dock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 females maintained their thresholds. A key finding was the emergence of more severe forebrain[->]brainstem seizures upon flurothyl retest in a significant percentage of mice across all groups. However, the proportion of mice developing these seizures did not differ significantly between genotypes. Although DOCK7 mutations have been linked to human epileptic encephalopathies and neurodevelopmental dysfunction, we find that Dock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 male and female mice do not show heightened excitability or seizure susceptibilities using the repeated flurothyl seizure model. HighlightsO_LIDock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 mice show slightly higher seizure thresholds during flurothyl kindling C_LIO_LIDock7{bigtriangleup}ex3-4/{bigtriangleup}ex3-4 mice do not exhibit heightened seizure susceptibility upon retest. C_LIO_LIForebrain-brainstem seizures emerged upon retest regardless of Dock7 genotype. C_LI

Disease variants in GABR genes encoding {gamma}-Aminobutyric acid type A receptor (GABAAR) subunits are major causes of developmental and epileptic encephalopathies (DEEs). There is no effective treatment for these DEEs although the GABAAR is a major target for antiseizure drugs. We previously identified the therapeutic effect of 4-phenyl-butyrate (PBA) in Gabrg2+/Q390X knockin DEE mice and now test the effect of the drug in GABRA1 variants that encode the 1 subunit. We used a multidisciplinary approach including in silico structural modeling, flow cytometry, patch clamp recordings and bio-chemistry in conjunction with differential tagging of the wild-type and the mutant alleles to evaluate the effect of PBA on rescue of GABAAR subunit expression, surface trafficking, and function in vitro in heterologous HEK293T cell model and in vivo in Gabra1+/A322D mice. We found that both total and cell surface 1 expression was reduced when the variant 1 protein was present; suggesting reduced functional receptor on the cell membrane and synapse. Patch clamp recordings identified 1 variants reduced GABA-evoked current amplitude. In silico prediction indicated reduced protein stability for GABRA1 variants indicated by negative {Delta}{Delta}G values. PBA increased both total and surface expression of wildtype 1 and 1 variants; and improved expression of both wildtype and variant 1 alleles when these were co-expressed. Importantly, PBA also increased the GABAAR expression in the thalamus of the Gabra1+/A322D mice. This study indicates that PBA is a promising treatment option for DEEs associated with GABRA1 mutations. Our previous work has demonstrated that PBA improves proteostasis by enhancing expression of the wildtype allele, repairing the mutant allele, and reducing endoplasmic reticulum stress. Therefore, it can mitigate seizures and improve neurobehavioral phenotypes at behavioral levels. Based on this and our previous work on GABRG2 and SLC6A1 mutations, we propose that PBA holds promise as a common medicine for multiple genetic neurologic disorders that share the proteostasis pathology with a broad clinical application in DEEs.

BackgroundIntegrating multimodal data into medical artificial intelligence (AI) tools and evaluating whether they outperform human experts remains a critical challenge. Epilepsy surgery offers a unique paradigm for this evaluation, as it provides an expert-independent measure (Engel score) of post-surgical outcome. Currently, evaluation for epilepsy surgery relies on the visual interpretation and human synthesis of multimodal data. While clinical evaluations are individualized and account for complex anatomical variability, integrating these diverse, high-dimensional modalities to generate a probability of surgical success remains challenging. Here, we leverage this objective outcome score to investigate the feasibility of a data-driven, phenotype-based model against the current clinical gold standard. MethodsThe evaluation was performed on an epilepsy-type controlled cohort of 57 patients from six tertiary epilepsy surgery centers who underwent resective/ablative surgery in the mesiotemporal lobe. Multimodal data, namely, patient demographics, semiology, invasive electrophysiology monitoring, and neuroimaging, were utilized. We first estimated how human experts perceive surgery success. Subsequently, we developed a data-driven model integrating these modalities to predict surgery outcomes. The model performance was compared to the current clinical gold standard (three independent human experts) and published outcome calculators. Finally, modality-level phenotypes were derived based on the models predictions. ResultsPredictions by human experts correlated poorly with post-surgical outcomes, and published outcome calculators did not perform better than the experts (DeLongs p = 0.367). Our model incorporating multimodal data achieved an area under the receiver operating characteristic curve (AUROC) of 0.801. It performed statistically better than the best human expert (DeLongs p = 0.043) and achieved a higher AUROC than the best published surgical outcome calculator (0.801 vs. 0.694). ConclusionsWe demonstrated the proof-of-concept that data-driven multimodal phenotypes can inform personalized surgery planning in epilepsy. Furthermore, we provide a framework for integrating multimodal data and benchmarking medical AI performance against human experts.

AIM: STXBP1-related disorder (STXBP1-RD) is a severe developmental and epileptic encephalopathy characterized by early-onset seizures and persistent cognitive and motor impairments. With disease-modifying trials emerging, a disorder-specific severity scale is needed. To address this, we adapted a validated clinician-reported measure from CDKL5 Deficiency Disorder to develop the STXBP1 Clinical Severity Assessment (S-CSA) and evaluated its psychometric properties. METHOD: The S-CSA was adapted from the CDKL5 Clinical Severity Assessment through expert consensus sessions with STXBP1 clinicians. Revisions addressed gaps in motor and vision domains, adding tremor and vision items. The measure was administered to 123 individuals with STXBP1-RD. Psychometric evaluation included confirmatory factor analysis, internal consistency, composite reliability, average variance extracted, and distinctiveness, compared with recommended thresholds. RESULTS: Analyses supported a three-domain structure (motor, communication, vision) with factor loadings >0.5 and strong internal consistency (Cronbachs alpha >0.7; composite reliability >0.88). Model fit and variance metrics met recommended standards, and domains demonstrated distinctiveness. No ceiling or floor effects were observed. Minimal skew was seen in motor (0.34) and communication (0.16) domains; positive skew in vision (2.2) was seen, identifying patients with and without cortical visual impairment. INTERPRETATION: The S-CSA demonstrates strong validity and reliability in STXBP1-RD and may show utility in clinical trials for STXBP1-RD and potentially other severe DEEs. Key Words: STXBP1-Related Disorder, Developmental and Epileptic Encephalopathies, Clinical Outcome Assessments

Objective: Electrical brain stimulations (EBS) are central to epileptic network identification and functional mapping during stereo-electroencephalography (SEEG), yet stimulation frequencies remain empirical, and standardized across patients and brain regions, producing false negatives and false positives, and potentially compromising surgical outcome. We investigated theta-range EBS (7 Hz) in the temporal lobe, a prominent physiological frequency band in this region, and compared it with conventional 1-Hz and 50-Hz protocols. Methods: We analyzed 1,408 temporal EBS in 25 patients with drug-resistant epilepsy. Epileptic responses (afterdischarges, seizures) and clinical signs were assessed across the epileptic network and temporal structures (amygdala, hippocampus, neocortex, parahippocampal gyrus, white matter), and analyzed according to stimulation parameters (frequency, intensity, duration, total charge). Results: At matched intensity and duration, 7-Hz EBS were associated with a higher occurrence of afterdischarges and clinical signs than 1-Hz EBS in several temporal structures (e.g., parahippocampal epileptogenic zone: p=0.014). Effects on usual seizure induction were less consistent. Comparisons with 50 Hz showed no systematic significant differences, with responses observed at one or both frequencies depending on structure and outcome. When controlling for total charge, frequency-related differences were attenuated. Some effects were sporadically observed at both intermediate frequency and charge quantity. No adverse events occured. Significance: Theta-range stimulation modulates electrophysiological and clinical responses during SEEG mapping and may provide complementary information to conventional frequencies. These findings support exploring a broader range of stimulation frequencies, rather than relying solely on standard protocols.

Background and PurposeWhile the idiopathic generalized epilepsy (IGE) comprise around one fifth of all epilepsy, the pathogenesis of it is largely unknown. Previous studies identified cognitive deficits in IGE patients, nevertheless, whether (and how) the brain structure and functional connectivity (FC) reflect these deficits remains underexplored. Here, we aim to find structural and FC differences in cognitively impaired IGE patients. Materials and MethodsWe recruited 36 IGE patients and 49 matched healthy controls (HC) in this cross-sectional study. All participants underwent structural and resting-state fMRI (rs-fMRI) scanning with a 3 Tesla MRI. Voxel-based morphometric analysis (VBM) was used to assessed structure differences, and seed-based analysis of rs-fMRI was used to examine FC. We examined the cognitive performance of patient with MoCA (Montreal Cognitive Assessment), grouped them into high (HMoCA, >25) and low (LMoCA, [&le;]25) group, and further examined the brain structural changes functional changes in each group. ResultsIGE patients showed right significant decrease in cerebellar gray matter volume (GMV), negatively correlating with the disease duration (r=-0.542, p=0.001), and increase in the left dorsolateral superior frontal gyrus GMV. Right cerebellum showed increased connectivity to the precuneus and angular gyrus, decreased connectivity to the postcentral gyrus and Rolandic operculum. Surprisingly, we found that LMoCA IGE patients (with more cognitive deficits) had increased right nucleus accumbens (NAc) GMV (t = -4.413, p < 0.001) and FC and a stronger NAc - prefrontal cortex FC (t = -2.683, p = 0.013), in comparison with the patients with high MoCA. ConclusionsCognitive impairment in IGE patients is linked to the NAc structural changes and NAc-prefrontal circuit alterations. These results provide novel circuit-level insights into understanding the cognitive impairment in IGE patients, contributing to revealing the pathophysiological mechanisms of IGE.

IntroductionTo leverage high-frequency oscillations (HFOs) as a biomarker with significant potential, this study compared a large set of detectors on a unified dataset, aiming to evaluate their clinical applicability under realistic conditions. MethodsEleven automatic detectors were applied to a retrospective dataset of intracranial and scalp EEGs from 27 consecutive pediatric patients. Inter-detector agreement was assessed using Spearmans Rho, and the area under the curve (AUC) for seizure onset zone (SOZ) prediction served as a consistent reference standard to enable reliable comparisons across recording modalities. Analyses were conducted separately for HFO and Spike-HFO detections. ResultsThe average age of our cohort was 12.4 years (SD 4.0; range 5-18). AUC values in scalp EEG ranged from 0.61 to 0.67 for HFOs and from 0.53 to 0.63 for Spike-HFO. AUC values in intracranial EEG ranged from 0.48 to 0.66 for HFOs and 0.54 to 0.69 in Spike-HFO. Although only three of the 11 detectors were specifically developed or adapted for scalp EEG, the detectors generally achieved higher AUC values and stronger agreement in scalp EEG ConclusionsWe present the first study comparing intracranial and scalp detectors by testing them beyond the modalities for which they were originally designed. Although the clinical utility of detections was comparable across EEG modalities, it remained lower than reported in original studies assessing the diagnostic value of HFOs. Caution is warranted when applying a publicly available detector to a new dataset, and detector robustness remains a critical issue. Key points- A comprehensive head-to-head comparison of 11 detectors demonstrated significant variability in detector agreement and clinical utility - Clinical utility was not necessarily linked to the EEG recording type the detector was originally designed for - Despite widely accepted use of automatic detections, detector robustness remains a critical issue

Objective: The postictal state is a major yet underrecognised component of epilepsy burden. We aimed to develop a structured patient-reported instrument to quantify postictal recovery, characterise its multidimensional burden and identify demographic, clinical, psychiatric and treatment-related factors associated with postictal severity and duration. Methods: We conducted a prospective, single-centre observational cohort study (Timone Hospital, Marseille, February 2025 - March 2026). Consecutive patients aged >=15 years admitted for scalp or stereo-EEG video-monitoring were included. Patients completed the Postictal Recovery Scale (PRS), an 11-domain questionnaire assessing fatigue, mood, sensory, motor, language, orientation, time perception and postictal amnesia. Items were rated from 0 (severe impairment) to 3 (no symptoms), yielding a total score of 0-33. Internal consistency was assessed using Cronbach alpha. Associations between PRS scores, subjective postictal duration and covariates were analysed using group comparisons, correlations and regression models. Results: Of 107 enrolled patients, 96 were included. PRS showed good internal consistency (Cronbach alpha; = 0.79). 96% of patients reported experiencing postictal symptoms, with fatigue (80%) and postictal amnesia (79%) being the most frequent and severe manifestations. Recovery exceeded one hour in 21% of patients. Greater postictal impairment was associated with higher interictal anxiety (Spearman {rho} = -0.32, p = 0.0018) and depressive symptoms (Spearman {rho} = -0.40, p = 0.0001), whereas demographic, epilepsy-related and treatment variables showed no significant associations. Altered postictal time perception was reported by 40% of patients and was associated with disorientation, but not psychiatric symptoms. Subjective postictal duration was longer than subjective ictal duration (Wilcoxon test, p < 0.0001). Significance: The postictal state is a frequent and multidimensional patient-reported experience. Greater postictal severity, particularly concerning anxiety and depression, is associated with interictal psychiatric comorbidity, while altered temporal experience emerges as a distinct dimension of postictal dysfunction. These findings support integrating postictal measures into clinical practice and trials.

Ferroptosis is a form of non-apoptotic cell death in which iron catalyzes the formation of reactive oxygen species, leading to lipid peroxidation. Experimentally, this process has recently been associated with seizures based on the increased levels of specific markers (4-hydroxynonenal and malondialdehyde) in the brain and plasma. Clinically, iron deposits have been identified in resected tissue from patients with refractory temporal lobe epilepsy. Quantitative susceptibility mapping (QSM) offers an opportunity to detect these accumulations in vivo. In this study, we investigated how pilocarpine-induced status epilepticus contributes to the generation of iron deposits in diverse cerebral regions and whether QSM can detect these deposits longitudinally. We scanned 14 animals (n=10 experimental; n=4 control) at five different time points (pre-status epilepticus induction and 1, 7, 14, 21 days post-induction) using QSM. We identified iron deposits in the caudate putamen, hippocampus, thalamus, and primary somatosensory cortex of experimental animals, which is consistent with histological findings. The initial size of the hippocampal iron deposits significantly increased over the following weeks. None of these effects was observed in the control animals. The presence of cerebral iron depositions in an animal model of pilocarpine-induced status epilepticus suggests that ferroptosis may be involved in the onset, development, and progression of spontaneous recurrent seizures. Furthermore, non-invasive, longitudinal in vivo mapping of brain iron deposits could be a potential imaging marker in neurological disorders such as epilepsy. Future experiments will be required to determine the origin of the iron and avoid its progressive accumulation. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=70 SRC="FIGDIR/small/712677v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@14abf67org.highwire.dtl.DTLVardef@5c08fborg.highwire.dtl.DTLVardef@51c40forg.highwire.dtl.DTLVardef@1eb5f9_HPS_FORMAT_FIGEXP M_FIG C_FIG

BackgroundIdiopathic epilepsy (IE) is the most common chronic nervous system disorder of dogs, and its cause is poorly understood. Emerging evidence suggests that microbiome alterations can occur with IE via the microbiota-gut-brain axis. Therefore, we analyzed the fecal microbiomes of 98 dogs (49 IE, 49 control) in a pairwise case-control observational study using 16S rRNA gene sequencing. ResultsAlthough the microbial community was mostly similar between groups, IE was associated with a modest but significant shift in Weighted-Unifrac distance (P = 0.042). We used six differential abundance (DA) methods to identify differentially abundant amplicon sequencing variants (ASVs) between IE and control groups. Notably, one Collinsella ASV was found to be significantly more abundant in IE dogs by all six methods. The gut microbial compositions varied drastically across households (accounting for about 69% of the total variation), but did not have significant differences between sex, age, or breed. Phenobarbital administration in IE dogs had a significant effect on seizure control, and was not associated with changes in the microbiome. ConclusionOur findings suggest a relationship between gut microbiomes and IE. However, the specific mechanism needs to be further investigated.

BackgroundDistinguishing epilepsy from functional/dissociative seizures (FDS) is an ongoing diagnostic challenge. Misdiagnosis delays appropriate treatment and puts patients at significant risk. Quantitative analyses of clinical EEG offer a potential avenue for developing decision-support tools in the diagnosis of seizure disorders. Recent work using univariate features demonstrated that reliably identifying diagnostic traits in the presence of confounding factors remains challenging. However, diagnostic information might be available in multivariate features such as network-based measures. Using a well-controlled dataset, we run the first diagnostic accuracy study assessing the potential of multivariate resting-state EEG markers to directly discriminate between a diagnosis of epilepsy and one of FDS at the time when a diagnosis is suspected and prior to treatment initiation. MethodsThe dataset, previously examined in a published study, includes 148 age- and sex-matched individuals with suspected seizure disorders who were later diagnosed with non-lesional epilepsy (n=75) or FDS (n=73). Eyes-closed, resting-state EEG data used for the analyses were normal on visual inspection, and acquired while participants were medication-free. Functional network measures in the 6-9 Hz range were extracted and machine learning implemented to assess their predictive potential; different model configurations (including varying model types, dimensionality reduction methods, and approaches to enhance feature stability) were tested to identify the most promising approach for future translational implementations. ResultsNetwork measures derived from resting-state EEG discriminate between conditions at levels significantly above chance (maximum balanced accuracy: 67.5%). Their sensitivity to epilepsy (81.8%) is consistently higher than their sensitivity to FDS (53.3%). A systematic assessment of model choices indicates that improving the temporal stability of network features through epoch-wise averaging improves classification accuracy (62.6% to 67.5%). Multiple nonlinear model types succeed on the classification problem, with the three-best performing assigning a consistent diagnostic label to 77.5% of the individuals; however, model choice remains a strong determinant of overall classification accuracy. Dimensionality reduction did not provide a significant advantage in our models. ConclusionWe establish evidence for the clinical validity of selected network-based markers to discriminate between a diagnosis of non-lesional epilepsy and FDS prior to treatment initiation, highlighting the measures potential to support post-test probability estimation in the clinic. Our models, configured to optimise balanced accuracy, classified people with epilepsy more accurately than people with FDS, indicating that these measures are specific to epilepsy and should not be interpreted as markers of a positive diagnosis of FDS.

BackgroundAttributional bias, a tendency to overinterpret others intentions as hostile (rather than situational or accidental), represents a component of social cognition and may affect everyday functioning. Neural models link attributional processing to fronto-temporal circuits and the default mode network, which are frequently altered in epilepsy. Difficulties in social participation and employment are common in people with epilepsy, and maladaptive attributional styles may contribute to these challenges. Attributional bias has not been systematically compared across epilepsy syndromes. MethodsWe examined attributional bias in 96 participants comprising 26 individuals with genetic generalised epilepsy (GGE), 27 with temporal lobe epilepsy (TLE), and 43 healthy controls (HC). Attributional style was assessed using the Ambiguous Intentions Hostility Questionnaire. Depressive symptoms were evaluated using the Neurological Disorders Depression Inventory in Epilepsy. Group differences were analysed, and potential clinical and demographical correlates were explored. ResultsThe GGE group exhibited higher hostility bias scores than HC (95% CI: 0.12-0.38, adjusted p = 0.014), whereas the difference between TLE and HC groups was moderate and not statistically significant (95% CI: 0.12-0.58, adjusted p = 0.059). Higher blame scores were positively associated with depressive symptoms (p = 0.016). Disease duration, seizure frequency, and antiseizure medication were not significantly associated with attributional bias. ConclusionsThese findings suggest that some individuals with genetic generalised epilepsy are more likely to interpret ambiguous situations as hostile. Altered attributional style may represent an under-recognised factor contributing to social difficulties in people with epilepsy and warrants further investigation as a potential target for psychosocial interventions. HighlightsO_LISome people with epilepsy are more prone to interpret social situations as hostile. C_LIO_LIHigher depression scores correlate with a tendency to blame external factors for misfortunes. C_LIO_LIDisease duration, antiseizure medication, and seizure frequency do not seem to influence the attributional bias. C_LI

1.PurposeSYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1-DEE) is characterized by high rates of both epilepsy and autism spectrum disorder (ASD). While the clinical spectrum is well-documented, the link between specific seizure semiologies and caregiver-reported autistic behaviors is not well understood. This study analyzed the correlation between ten distinct seizure types, their frequencies, and a caregiver-reported autistic behavior score. MethodClinical data were extracted from the PATRE (PATient-based phenotyping and evaluation of therapy for Rare Epilepsies) Registry for SYNGAP1, in the framework of the EURAS project (Grant No. 101080580, Horizon Europe). This study employed a retrospective cross-sectional analysis of caregiver-reported registry data. Analysis was restricted to an analytic cohort of N=337 participants with complete data for both the epilepsy questionnaire (including epilepsy status, seizure semiology, and peak seizure frequency items) and the behavior questionnaire (from a total N=522 registry participants). Caregiver-reported autistic behaviors were quantified using a standardized caregiver-reported scale (Likert 1-5). Statistical associations were evaluated using the Wilcoxon rank-sum test to compare caregiver-reported autistic behavior scores across different seizure semiologies and Spearmans rank correlation to assess the impact of seizure frequency (9-point scale). ResultsWithin the analytic cohort (N=337), epilepsy was reported in 259 patients. Eyelid myoclonia was the most prevalent semiology, affecting 64.9% (n=168) of the epilepsy-positive group. Atypical absences (n=77) demonstrated the most profound and statistically robust association with higher caregiver-reported autistic behavior scores (FDR-adjusted p = 0.001). Significant associations were also observed for typical absences (n=70, FDR-adjusted p = 0.018), eyelid myoclonia (FDR-adjusted p = 0.018), myoclonic-atonic seizures (n=40, FDR-adjusted p = 0.019), and atonic seizures (n=72, FDR-adjusted p = 0.025). Focal and tonic-clonic seizures showed weaker associations (FDR-adjusted p = 0.026 and p = 0.047, respectively). Crucially, quantitative analysis revealed no significant correlation between ordinal caregiver-reported peak seizure frequency ratings and caregiver-reported autistic behavior scores across all semiologies (e.g., Eyelid Myoclonia: p=0.096; Atypical Absences: p=0.744), indicating no detectable association between peak-frequency ratings and caregiver-reported autistic behavior scores. ConclusionHigher caregiver-reported autistic behavior scores in SYNGAP1-DEE were most strongly associated with the presence of atypical absences, representing a generalized, thalamocortical seizure network dysfunction. In contrast, no detectable association was observed between caregiver-reported autistic behavior scores and the ordinal caregiver-reported peak seizure frequency metric. Atypical absences and related semiologies may serve as clinical "red flags" for increased neurodevelopmental comorbidity severity, regardless of reported peak seizure frequency. Abstract SummaryThis study investigates the relationship between ten seizure semiologies, seizure frequency, and severity of caregiver-reported autistic behaviors in a large-scale international cohort of N=337 patients with SYNGAP1-DEE. We identify a robust association between elevated caregiverreported autistic behavior scores and specific thalamocortical seizure patterns, most prominently atypical absences. Notably, our analysis reveals that this association is independent of seizure frequency, demonstrating no detectable association between this ordinal, caregiver-reported seizure frequency metric and caregiver-reported autistic behaviors.